Ovarian cancer

82 total trials 41 recruiting MedDRA PT

Filter these 82 trials by phase, country, sponsor and more.

Open in Search →

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Dru … Ended

2024-513708-33-00 1 2022-11-23 "Advanced Epithelial Ovarian Cancer (including Fallopian Tube"
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors Ended

2022-500094-14-00 1 2022-11-08 "gastroesophageal junction [GEJ] carcinoma"
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended

2024-511750-53-00 7 2022-09-08 "Unresectable Locally Advanced or Metastatic Cancer"
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination … Ended

2024-511744-27-00 1 2022-06-27 "Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, E"
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended

2024-512639-58-00 7 2022-05-07 "Solid Tumors"
"OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T … Ended

2023-505097-16-00 4 2022-04-04 "Ovarian Neoplasms"
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selecte … Ended

2024-513915-28-00 3 2019-06-14 "Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epith"
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended

2023-508010-42-00 5 2016-09-14 "Homologous recombination deficiency advanced ovarian cancer"
CheckMate 032:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 032 Ended

2024-516540-25-00 9 2013-12-11 "Advanced or metastatic solid tumors: 1) Triple Negative Brea"
A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors Ended

2022-502622-40-00 1 "Advanced Solid Tumors"

Showing 73–82 of 82 trials